Challenges in Rare Diseases Treatment

\r\n There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

\r\n

    Related Conference of Challenges in Rare Diseases Treatment

    August 19-20, 2020

    European Summit on HIV, STD and STIs

    Milan, Italy
    September 28-29, 2020

    13th Global Infections Conference

    Singapore
    October 5-6, 2020

    12th Euro-Global Conference on Infectious Diseases

    Vienna, Austria
    November 05-06, 2020

    9th Asia Pacific STD and Infectious Diseases Congress

    Tokyo, Japan
    February 15-16, 2021

    8th International Congress on Infectious Diseases

    London, UK
    February 22-23, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore

    Challenges in Rare Diseases Treatment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in